A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use
NCT03145857
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
1534
Enrollment
OTHER
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
[68]Ga-HA-DOTATATE
Sponsor
AHS Cancer Control Alberta